These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 23061913

  • 1. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE, Garay OU, Calderón M, Pichón-Riviére A, Augustovski F, Martí SG, Cortiñas P, Gonzalez M, Naranjo LT, Gomez JA, Caporale JE.
    BMC Public Health; 2017 Feb 02; 17(1):152. PubMed ID: 28148228
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen YC, Li X, Van Kriekinge G, Lee IH.
    Hum Vaccin Immunother; 2017 May 04; 13(5):1158-1166. PubMed ID: 28075249
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.
    Vaccine; 2013 Aug 20; 31(37):3863-71. PubMed ID: 23830974
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.
    Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N.
    BMC Public Health; 2009 Oct 31; 9():401. PubMed ID: 19878578
    [Abstract] [Full Text] [Related]

  • 12. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.
    Lee H, Hur S, Jang H, Lee IH, Sohn WY, Van Kriekinge G, Kim BG.
    Asian Pac J Cancer Prev; 2019 Feb 26; 20(2):425-435. PubMed ID: 30803204
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK, Lee BW, Sohn WY, Lee IH, Mathur G, Sanicas M, Van Kriekinge G.
    Singapore Med J; 2018 Jul 26; 59(7):370-382. PubMed ID: 28983579
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.
    Vokó Z, Nagyjánosi L, Kaló Z.
    BMC Public Health; 2012 Oct 30; 12():924. PubMed ID: 23110361
    [Abstract] [Full Text] [Related]

  • 16. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
    Brisson M, Van de Velde N, De Wals P, Boily MC.
    Vaccine; 2007 Jul 20; 25(29):5399-408. PubMed ID: 17561316
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ, Tay SK, Teoh YL, Tok MY.
    BMC Public Health; 2011 Mar 31; 11():203. PubMed ID: 21453537
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH, Cheng WF, Jiang JH, You SL, Huang LW, Hsieh JY, Mukherjee P, Van Kriekinge G, Lee C.
    Asian Pac J Cancer Prev; 2019 May 25; 20(5):1377-1387. PubMed ID: 31127896
    [Abstract] [Full Text] [Related]

  • 19. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N.
    Vaccine; 2014 Feb 03; 32(6):733-9. PubMed ID: 24291200
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X, Stander MP, Van Kriekinge G, Demarteau N.
    BMC Infect Dis; 2015 Dec 11; 15():566. PubMed ID: 26652918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.